TY - JOUR
T1 - Altered patterns of phosphorylation in cultured mouse lenses during development of buthionine sulfoximine cataracts
AU - Li, Wenjie
AU - Calvin, Harold I.
AU - David, Larry L.
AU - Wu, Kaili
AU - McCormack, Ashley L.
AU - Zhu, Guan Ping
AU - Joseph Fu, S. C.
N1 - Funding Information:
This work was supported in part by NIH R01grants EY-07355 (HIC), and EY-12016 (LLD); NIH P30 Core grant EY-10572 (OHSU); and by grants from Research to Prevent Blindness and from the New Jersey Lions Eye Research Foundation to the Department of Ophthalmology, UMDNJ-New Jersey Medical School. The authors thank Dr Paul FitzGerald of University of California, Davis, CA, U.S.A. for antibodies to filensin peptides and Dr J. Samuel Zigler of the National Eye Institute for antibodies to alpha and beta crystallins.
PY - 2002
Y1 - 2002
N2 - Buthionine sulfoximine (BSO), a specific inhibitor of glutathione biosynthesis, induces oxidative cataracts following multiple injections into mice at 1 week of age. Cultures of lenses with 35S-methionine have previously demonstrated altered patterns of protein biosynthesis that precede and accompany these cataracts. To obtain parallel information about changes in protein phosphorylation during cataract development, lenses from BSO-treated or control mouse pups were cultured for 3 hr at 37°C with 32Pi, homogenized in phosphate buffer, and resolved by centrifugation into water-soluble (WS) and water-insoluble (WI) fractions. These were characterized by 2D-gel electrophoresis, Coomassie blue staining, phosphorimaging, immunoblotting, and tandem mass spectrometry. Heaviest labelling was in the WI fraction. The labelled 2D-gel spots included: (1) a series of phosphorylated filensins at 95 kDa; (2) a major radioactive spot at 45-50 kDa, slightly anodic to actin and the beaded filament protein, phakinin (CP 49); (3) a phosphorylated betaB1-crystallin, considerably anodic to parent betaB1; (4) an acidic cluster of labelled alphaA-crystallins, phosphorylated in part at serine-148, and (5) a labelled trace alpha crystallin, slightly anodic to alphaB-crystallin. The results confirm previously reported phosphorylations of actin, phakinin, alphaA- and alphaB-crystallin, demonstrate previously unrecognized phosphorylations of filensin and betaB1-crystallin, and provide unequivocal evidence for phosphorylation of alphaA-crystallin at serine-148. The earliest changes in phosphorylation detected after BSO treatment were increased labelling of alphaA- and alphaB-crystallin during cataract stages 1-3, coupled with a general decrease in protein labelling. In stage 5 cataracts, phosphorylated alpha crystallins persisted as the dominant labelled species. However, the major modifications of alphaA-crystallin in advanced BSO cataracts were unlabelled and partially degraded, in contrast to phosphorylated alphaA. It is therefore proposed that phosphorylation of alphaA-crystallin may confer resistance to proteolytic degradation.
AB - Buthionine sulfoximine (BSO), a specific inhibitor of glutathione biosynthesis, induces oxidative cataracts following multiple injections into mice at 1 week of age. Cultures of lenses with 35S-methionine have previously demonstrated altered patterns of protein biosynthesis that precede and accompany these cataracts. To obtain parallel information about changes in protein phosphorylation during cataract development, lenses from BSO-treated or control mouse pups were cultured for 3 hr at 37°C with 32Pi, homogenized in phosphate buffer, and resolved by centrifugation into water-soluble (WS) and water-insoluble (WI) fractions. These were characterized by 2D-gel electrophoresis, Coomassie blue staining, phosphorimaging, immunoblotting, and tandem mass spectrometry. Heaviest labelling was in the WI fraction. The labelled 2D-gel spots included: (1) a series of phosphorylated filensins at 95 kDa; (2) a major radioactive spot at 45-50 kDa, slightly anodic to actin and the beaded filament protein, phakinin (CP 49); (3) a phosphorylated betaB1-crystallin, considerably anodic to parent betaB1; (4) an acidic cluster of labelled alphaA-crystallins, phosphorylated in part at serine-148, and (5) a labelled trace alpha crystallin, slightly anodic to alphaB-crystallin. The results confirm previously reported phosphorylations of actin, phakinin, alphaA- and alphaB-crystallin, demonstrate previously unrecognized phosphorylations of filensin and betaB1-crystallin, and provide unequivocal evidence for phosphorylation of alphaA-crystallin at serine-148. The earliest changes in phosphorylation detected after BSO treatment were increased labelling of alphaA- and alphaB-crystallin during cataract stages 1-3, coupled with a general decrease in protein labelling. In stage 5 cataracts, phosphorylated alpha crystallins persisted as the dominant labelled species. However, the major modifications of alphaA-crystallin in advanced BSO cataracts were unlabelled and partially degraded, in contrast to phosphorylated alphaA. It is therefore proposed that phosphorylation of alphaA-crystallin may confer resistance to proteolytic degradation.
KW - 2D-gel electrophoresis
KW - Actin
KW - Alpha crystallin
KW - Beta crystallin
KW - Buthionine sulfoximine
KW - Cataract
KW - Filensin
KW - Immunoblot
KW - Lens
KW - Mouse
KW - Phakinin
KW - Phosphorimage
KW - Phosphorylation
KW - Tandem mass spectrometry
UR - http://www.scopus.com/inward/record.url?scp=0036402462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036402462&partnerID=8YFLogxK
U2 - 10.1016/S0014-4835(02)92008-7
DO - 10.1016/S0014-4835(02)92008-7
M3 - Article
C2 - 12384096
AN - SCOPUS:0036402462
SN - 0014-4835
VL - 75
SP - 335
EP - 346
JO - Experimental Eye Research
JF - Experimental Eye Research
IS - 3
ER -